Kopra Bio is a UCSF spinout and Y Combinator-backed biotech developing viral immunotherapies for cancer. Its proprietary InViTE (In Vivo Tumor Editing) platform uses genetically engineered viruses designed to selectively infect and destroy tumor cells, starting with glioblastoma.
Company Info
Funding & Investor Relations
Upcoming Milestones & Key Dates
Phase 1 trial initiation in China (glioblastoma)
First patient dosed in Phase 1 China trial
Clinical Development Pipeline
Recent News
Kopra Bio, a UCSF spinout developing viral immunotherapy for glioblastoma, has raised $9.1M to begin a China clinical trial of its InViTE platform that uses genetically engineered viruses to selectively destroy tumor cells.
Leadership Team
Co-Founder & CEO
Scientific founders (InViTE platform)
Careers & Job Openings